Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Apr-09 4:05 PM View:  | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 09-Apr-09 | Payment of Exercise | 5,950 | $19.94 | $118,643.00 | (7%) 80.11K to 74.16K | (< 1%) |
| 09-Apr-09 4:05 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 09-Apr-09 | Payment of Exercise | 20,278 | $19.94 | $404,343.00 | (4%) 510.26K to 489.98K | (< 1%) |
| 09-Apr-09 4:04 PM View: | Stuart Lewis J SVP COMMERCIAL OPERATIONS | CV Therapeutics, Inc. (CVTX) | 08-Apr-09 | Payment of Exercise | 84,014 | $19.94 | $1,675,240.00 | (59%) 141.79K to 57.77K | (< 1%) |
| 09-Apr-09 4:04 PM View: | Stuart Lewis J SVP COMMERCIAL OPERATIONS | CV Therapeutics, Inc. (CVTX) | 08-Apr-09 | Option Exercise | 117,058 | $10.90 | $1,275,880.00 | 473% 24.73K to 141.79K | 83% |
| 09-Apr-09 4:02 PM View: | Shenk Thomas E Director | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Option Exercise | 7,500 | $19.91 | $149,325.00 | 13% 56.0K to 63.5K | < 1% |
| 09-Apr-09 4:03 PM View: | Gutshall Thomas L Director | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Payment of Exercise | 40,848 | $19.94 | $814,509.00 | (48%) 85.21K to 44.36K | (< 1%) |
| 09-Apr-09 4:02 PM View: | Shenk Thomas E Director | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Option Exercise | 27,500 | $11.08 | $304,625.00 | (77%) 35.57K to 8.07K | (80%) |
| 09-Apr-09 4:03 PM View: | Gutshall Thomas L Director | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Option Exercise | 50,000 | $13.57 | $678,500.00 | 142% 35.21K to 85.21K | 47% |
| 09-Apr-09 4:02 PM View: | Shenk Thomas E Director | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Payment of Exercise | 27,927 | $19.94 | $556,864.00 | (44%) 63.5K to 35.57K | (< 1%) |
| 06-Apr-09 7:49 PM View: | Costa Santo J Director | CV Therapeutics, Inc. (CVTX) | 06-Apr-09 | Option Exercise | 50,000 | $13.57 | $678,500.00 | 100% 0 to 50.0K | 47% |
| 06-Apr-09 7:49 PM View: | Costa Santo J Director | CV Therapeutics, Inc. (CVTX) | 06-Apr-09 | Payment of Exercise | 40,854 | $19.93 | $814,220.00 | (82%) 50.0K to 9.15K | (< 1%) |
| 03-Apr-09 6:34 PM View: | Lee Kenneth B Jr Director | CV Therapeutics, Inc. (CVTX) | 03-Apr-09 | Payment of Exercise | 45,155 | $19.92 | $899,488.00 | (79%) 56.83K to 11.67K | (< 1%) |
| 03-Apr-09 6:34 PM View: | Lee Kenneth B Jr Director | CV Therapeutics, Inc. (CVTX) | 03-Apr-09 | Option Exercise | 56,250 | $13.03 | $733,125.00 | 9783% 0.57K to 56.83K | 53% |
| 03-Apr-09 2:19 PM View: | Davie Joseph Md Phd Director | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Option Exercise | 27,500 | $11.08 | $304,625.00 | 100% 0 to 27.5K | 80% |
| 03-Apr-09 2:17 PM View: | Suvari Tricia Borga SVP, General Counsel & Sec | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Option Exercise | 163,958 | $11.54 | $1,892,060.00 | 772% 21.25K to 185.21K | 73% |
| 03-Apr-09 2:15 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Option Exercise | 188,958 | $11.75 | $2,221,060.00 | 587% 32.18K to 221.14K | 70% |
| 03-Apr-09 2:14 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Option Exercise | 641,083 | $12.00 | $7,693,930.00 | 184% 348.35K to 989.43K | 66% |
| 03-Apr-09 2:16 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Payment of Exercise | 163,958 | $19.91 | $3,264,400.00 | (63%) 258.43K to 94.47K | (< 1%) |
| 03-Apr-09 2:17 PM View: | Suvari Tricia Borga SVP, General Counsel & Sec | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Payment of Exercise | 121,191 | $19.91 | $2,412,910.00 | (65%) 185.21K to 64.02K | (< 1%) |
| 03-Apr-09 2:16 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Option Exercise | 213,958 | $12.37 | $2,646,810.00 | 481% 44.47K to 258.43K | 61% |
| 03-Apr-09 2:15 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Market Option Sale | 141,029 | $19.91 | $2,807,890.00 | (64%) 221.14K to 80.11K | (< 1%) |
| 03-Apr-09 2:14 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Market Option Sale | 479,175 | $19.90 | $9,535,580.00 | (48%) 989.43K to 510.26K | (< 1%) |
| 03-Apr-09 2:19 PM View: | Davie Joseph Md Phd Director | CV Therapeutics, Inc. (CVTX) | 02-Apr-09 | Payment of Exercise | 20,435 | $19.92 | $407,065.00 | (74%) 27.5K to 7.07K | (< 1%) |
| 26-Mar-09 1:07 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 25-Mar-09 | Option Exercise | 11,345 | $19.88 | $225,539.00 | 3% 342.03K to 353.37K | < 1% |
| 26-Mar-09 1:07 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 25-Mar-09 | Payment of Exercise | 5,025 | $19.88 | $99,897.00 | (1%) 353.37K to 348.35K | (< 1%) |
| 26-Feb-09 3:23 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Payment of Exercise | 4,317 | $15.58 | $67,258.90 | (9%) 48.79K to 44.47K | (28%) |
| 26-Feb-09 3:23 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Option Exercise | 12,499 | $15.58 | $194,734.00 | 34% 36.29K to 48.79K | 28% |
| 26-Feb-09 3:22 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Option Exercise | 50,000 | $15.58 | $779,000.00 | 16% 314.3K to 364.3K | 28% |
| 26-Feb-09 3:23 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Payment of Exercise | 4,317 | $15.58 | $67,258.90 | (12%) 36.5K to 32.18K | (28%) |
| 26-Feb-09 3:22 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Payment of Exercise | 22,270 | $15.58 | $346,967.00 | (6%) 364.3K to 342.03K | (28%) |
| 26-Feb-09 3:24 PM View: | Suvari Tricia Borga SVP, General Counsel & Sec | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Option Exercise | 12,499 | $15.58 | $194,734.00 | 96% 13.07K to 25.57K | 28% |
| 26-Feb-09 3:23 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 25-Feb-09 | Option Exercise | 12,499 | $15.58 | $194,734.00 | 52% 24.0K to 36.5K | 28% |
| 09-Feb-09 4:42 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 06-Feb-09 | Market Sale (Planned) | 1,500 | $15.50 | $23,250.00 | (4%) 37.79K to 36.29K | (29%) |
| 20-Jan-09 3:10 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 15-Jan-09 | Option Exercise | 801 | $9.33 | $7,473.33 | < 1% 311.48K to 312.28K | 114% |
| 20-Jan-09 3:10 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 15-Jan-09 | Payment of Exercise | 286 | $9.33 | $2,668.38 | (< 1%) 312.28K to 311.99K | (114%) |
| 07-Jan-09 7:10 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 07-Jan-09 | Market Sale (Planned) | 1,500 | $9.38 | $14,070.00 | (4%) 37.61K to 36.11K | (113%) |
| 23-Dec-08 4:00 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 22-Dec-08 | Option Exercise | 11,346 | $8.91 | $101,093.00 | 4% 303.48K to 314.82K | 125% |
| 23-Dec-08 4:00 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 22-Dec-08 | Payment of Exercise | 5,026 | $8.91 | $44,781.70 | (2%) 314.82K to 309.8K | (125%) |
| 12-Feb-09 7:33 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 12-Dec-08 | Gift | 2,000 | $9.15 | $18,300.00 | (8%) 25.25K to 23.25K | (119%) |
| 15-Dec-08 4:39 PM View: | Stuart Lewis J SVP COMMERCIAL OPERATIONS | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Option Exercise | 2,700 | $8.48 | $22,896.00 | 15% 17.48K to 20.18K | 136% |
| 15-Dec-08 4:34 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Payment of Exercise | 1,787 | $8.48 | $15,153.80 | (7%) 25.3K to 23.51K | (136%) |
| 15-Dec-08 4:39 PM View: | Suvari Tricia Borga SVP, General Counsel & Sec | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Option Exercise | 5,000 | $8.48 | $42,400.00 | 61% 8.18K to 13.18K | 136% |
| 15-Dec-08 4:34 PM View: | Spiegelman Daniel K SVP, CFO | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Option Exercise | 5,000 | $8.48 | $42,400.00 | 25% 20.3K to 25.3K | 136% |
| 15-Dec-08 4:39 PM View: | Stuart Lewis J SVP COMMERCIAL OPERATIONS | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Payment of Exercise | 965 | $8.48 | $8,183.20 | (5%) 20.18K to 19.21K | (136%) |
| 15-Dec-08 4:28 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Option Exercise | 12,000 | $8.48 | $101,760.00 | 4% 297.01K to 309.01K | 136% |
| 15-Dec-08 4:38 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Payment of Exercise | 1,787 | $8.48 | $15,153.80 | (5%) 39.4K to 37.61K | (136%) |
| 15-Dec-08 4:28 PM View: | Lange Louis G Chairman & CEO Director | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Payment of Exercise | 5,490 | $8.48 | $46,555.20 | (2%) 309.01K to 303.52K | (136%) |
| 15-Dec-08 4:39 PM View: | Suvari Tricia Borga SVP, General Counsel & Sec | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Payment of Exercise | 1,787 | $8.48 | $15,153.80 | (14%) 13.18K to 11.39K | (136%) |
| 15-Dec-08 4:38 PM View: | Blackburn Brent K SVP, Drug Discovery & Dev | CV Therapeutics, Inc. (CVTX) | 11-Dec-08 | Option Exercise | 5,000 | $8.48 | $42,400.00 | 15% 34.4K to 39.4K | 136% |
| 10-Dec-08 5:52 PM View: | Stuart Lewis J SVP COMMERCIAL OPERATIONS | CV Therapeutics, Inc. (CVTX) | 10-Dec-08 | Market Option Sale | 700 | $9.23 | $6,461.00 | (4%) 18.48K to 17.78K | (117%) |
